Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 67

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Non-small cell lung cancer

Recruiting

Study of Durvalumab for Patients with Early Stage or Locally Advanced Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.

Neuroendocrine tumour+1

Recruiting

Study on Aldesleukin and Dendritic Cell Vaccine for Patients with Resected Stage IV Neuroendocrine Tumors and Soft Tissue Sarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Neoplasm malignant+1

Recruiting

Study on the Diagnostic Performance of 68Ga-ABS011 PET/CT for Patients with Metastatic Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:68GA-NOTA-abscint-HER2
  • Sponsor:Abscint

Acute myeloid leukaemia

Recruiting

Study on Teicoplanin for Preventing Infections in Children with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teicoplanin
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

T-cell type acute leukaemia+1

Recruiting

Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
  • Sponsor:Onechain Immunotherapeutics S.L.

Adenocarcinoma gastric+13

Recruiting

Study of JK06 for Patients with Advanced or Metastatic Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:JK06
  • Sponsor:Salubris Biotherapeutics Inc.

Rectal cancer+1

Recruiting

Study on Encorafenib and Cetuximab for Patients with BRAF V600E-Mutated Localized Colon or Upper Rectum Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Neoplasm malignant

Recruiting

Study of ART6043, Olaparib, and Niraparib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ART6043
  • Sponsor:Artios Pharma Limited

Acute lymphocytic leukaemia+2

Recruiting

Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:AUTO4
  • Sponsor:Autolus Limited

Neoplasm+2

Recruiting

Study on APL-101 for Treating Advanced Solid Tumors and Non-Small Cell Lung Cancer with MET Changes in Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:APL-101
  • Sponsor:Apollomics Inc.

Peripheral T-cell lymphoma unspecified

Recruiting

Study on the Effectiveness and Safety of Belinostat and Pralatrexate with Drug Combination for Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belinostat
  • Sponsor:Acrotech Biopharma Inc.

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib for Adults with Chronic Lymphocytic Leukemia and Heart Issues

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.